Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema.
Platelet activating factor (PAF), a potent lipid-like vasoactive agent, induced rat foot edema when it was injected subplantarly. The edema reached its maximum 1 h after PAF challenge. Indomethacin did not inhibit the peak edematous response whereas both PAF antagonists, kadsurenone and L-652,731, inhibit the PAF-induced rat foot edema (PFE). Both PAF antagonists also partially block the first phase of the carrageenin-induced rat foot edema (CFE). Using the inhibition of [3H]PAF receptor binding to prepared rabbit platelet membranes, release of PAF or PAF-like materials in carrageenin-injected rat hindpaw was observed. These results suggest that the released PAF or PAF-like materials together with the released histamine and kinin evoke the first phase hindpaw edema in the rats. Indomethacin or PAF antagonist, administered alone, does not block the first phase or the second phase of CFE, respectively. However, PAF antagonist potentiated the inhibitory effects of indomethacin suggesting that the released PAF may also be involved in the biosynthesis of prostaglandins to initiate the second phase of rat CFE.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001572:Benzofurans; D001578:Benzopyrans / Q000494:pharmacology; D002351:Carrageenan; D004487:Edema / Q000503:physiopathology*; D017705:Lignans; D008297:Male; D010972:Platelet Activating Factor / Q000378:metabolism* / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D001572:Benzofurans; D001578:Benzopyrans; D017705:Lignans; D010972:Platelet Activating Factor; D002351:Carrageenan; C044540:kadsurenone